A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer

This study is being done to answer the following question:
Will ado-trastuzumab emtansine (T-DM1) extend the length of time without your cancer getting worse compared to the usual approach?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your type of salivary gland cancer. The usual approach is defined as care most people get for salivary gland cancer that is HER2-positive and has come back, spread, or cannot be removed by surgery.